Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Cardiovascular Diseases

Cordis FDA Approval for MYNX CONTROL VENOUS Vas...

Cordis Secured FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device, Expanding Proven MYNX Technology to Mid-Bore Venous Puncture Sites On July 9, 2024, Cordis, a leading company in cardiov...

Jul 11, 2024

rise-of-energy-drinks
The Rise of Energy Drinks: Power in a Can or a Health Hazard?

Energy drinks have become a ubiquitous part of modern life, promising quick boosts of energy, enhanced mental alertness, and improved physical performance. These beverages are particularly popular among young adults, athletes, and professionals who often face demanding schedules and high levels of stress. However, ...

Find More
pharma-news-for-eisai-merck-verona-astrazeneca
Eisai Announces Solo Development of Farletuzumab Ecteribulin (FZEC); Johnson & Johnson’s Nipocalimab Phase III Trial; Merck’s WINREVAIR  EU CHMP Recommendation;  Verona Pharma’s  Ohtuvayre FDA Approval; AstraZeneca’s Lynparza and Imfinzi EU Approval

Eisai Announces Solo Venture for Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate Eisai Co., Ltd. announced the termination of its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), previously known as MORAb-202, an ...

Find More
pharma-news-for-alnylam-bms-daichii-sankyo-vertex
Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval

Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...

Find More

More Views & Analysis

evolving-dilated-cardiomyopathy-treatment
Revolutionizing Dilated Cardiomyopathy Treatment: The Road Ahead

Quick facts The primary cause of DCM is understood to be genetic, leading to a focus on tailoring treatments based on the specific molecular origin. Genetic testing plays a crucial role in DCM, as numerous studies and case reports have demonstrated, serving as a vital tool for diagnosis, prognosis, familial scr...

Find More

medtech-news-for-boston-scientific-corporation-philips-akili-roche
Boston Scientific Corporation Agreement to Acquire Silk Road Medical; Philips Introduced Duo Venous Stent System; Akili’s EndeavorOTC Received FDA Clearance; Roche Achieved FDA Clearance; atHeart Medical Reported Long and Short-term Clinical Data; Bioretec Announced Successful Clinical Outcomes

Boston Scientific Corporation Announced Definitive Agreement to Acquire Silk Road Medical, Inc., an Innovator in Stroke Prevention Technology On June 18, 2024, Boston Scientific Corporation, a global leader in medical technologies, announced the formal agreement to acquire Silk Medical, Inc., a medical device co...

Find More

winrevair-for-pulmonary-arterial-hypertension-treatment
WINREVAIR Approval for Pulmonary Arterial Hypertension Treatment: Is It A Game-Changer for Merck?

Merck’s investment of $11.5 billion in acquiring Acceleron Pharma is expected to yield significant returns with the FDA’s approval of WINREVAIR (sotatercept), a pivotal component of the acquisition, for the treatment of pulmonary arterial hypertension. An estimated prevalence of pulmonary hypertension at the pop...

Find More

medtech-news-for-asensus-surgical-allosource-abbott-foldax
Asensus Surgical Acquired by Karl Storz; Allosource® Launched Aceconnex®; Siemens Healthineers FDA Clearance for Chiller-Free Biograph Trinion PET/CT; Abbott Received FDA Clearance; Foldax® Reported Positive Clinical Results; Amber Implants Completed Enrolment of First-In-Human Clinical Trial

Asensus Surgical Agreed to be Acquired by Karl Storz  On June 07, 2024, Asensus Surgical announced that it had entered a deal in which Karl Storz would acquire the company for 35¢ per share in cash. Karl Storz Endoscopy-America, a wholly-owned subsidiary of Germany-based Karl Storz, had agreed to acquire...

Find More

medtech-news-for-nikon-teijin-spineart-ceretrieve
Solis Mammography’s Acquisition of MUSIC Imaging Center; Nikon’s SI-PH Phase Condenser Accessory Option; Teijin Launch Surgical Patch; Terumo Cardiovascular’s FDA 510(K) Clearance; Spineart’s 510(k) Clearance; Ceretrieve’s Success in FIH Ischemic Stroke Cases

Solis Mammography Announced Acquisition of MUSIC Imaging Center in Gainesville, Florida  On May 28, 2024, Solis Mammography announced the acquisition of the MUSIC Mammography and Ultrasound Imaging Center in Gainesville, Florida. For more than 10 years, MUSIC has provided patients with an advanced standard ...

Find More

insights-into-artificial-blood-vessels
From Lab to Lifesaver: Advancing Artificial Blood Vessels for Healthier Tomorrows

Artificial blood vessels are at the forefront of medical innovation, offering a lifeline to millions worldwide. With advancements in bioengineering, these synthetic conduits are shaping a new era in healthcare, promising solutions to cardiovascular diseases and beyond. Artificial blood vessels represent a revolu...

Find More

The Union of the European countries, also known as the European Union or the EU, is more or less lik.....

Find More

Toll-like Receptors (TLRs) are a type of pattern recognition receptor (PRR) that recognizes pathogen.....

Find More

Though Covid-19 has a significant impact on the supply chain, input costs, logistics, and raw materi.....

Find More

Well, MDS being one of the rare blood cancers, has been into the limelight of researchers since a de.....

Find More

Herpes zoster oticus (HZ oticus) is a viral infection of the inner, middle, and external ear. A resu.....

Find More

The convergence of technologies and the increasing integration of medical devices to computer networ.....

Find More